Suggested remit: To appraise the clinical and cost effectiveness of levodopa, carbidopa monohydrate and entacapone within its marketing authorisation for treating the symptoms of advanced Parkinson’s disease
- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- ID number:
- 4005
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 July 2022 | Note added to the project documents |
| 11 July 2022 | Topic selection. Change TS decision to deselected |
| 03 May 2022 (10:00) | Scoping workshop |
| 15 March 2022 - 12 April 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 15 March 2022 | In progress. Scoping commenced |
| 15 March 2022 | In progress. Scoping commenced |
| 28 January 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on how we select topics for development, please see our page about topic prioritisation